REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses
Robbins LLP is reminding investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The lawsuit alleges that Regeneron misled investors about its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma, specifically regarding statistical assumptions and clinical differentiation. …